2023
DOI: 10.1016/j.bioorg.2023.106362
|View full text |Cite
|
Sign up to set email alerts
|

Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 80 publications
0
3
0
Order By: Relevance
“…Recently, a study on the potential anti-inflammatory activity of some phenolic and methide-quinone nor -triterpenes isolated from Maytenus retusa that were evaluated for the inhibition of the NLRP3 inflammasome in macrophages appeared [ 35 ]. One of the most potent compounds evaluated was a semisynthetic methide-quinone Br derivative related to the three methide-quinones described in this work.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, a study on the potential anti-inflammatory activity of some phenolic and methide-quinone nor -triterpenes isolated from Maytenus retusa that were evaluated for the inhibition of the NLRP3 inflammasome in macrophages appeared [ 35 ]. One of the most potent compounds evaluated was a semisynthetic methide-quinone Br derivative related to the three methide-quinones described in this work.…”
Section: Discussionmentioning
confidence: 99%
“…The calculated binding energies of these three compounds are −13.7 kcal/mol for hydroxytingenone, −11.8 and 13.0 kcal/mol for tingenone, and −9.3 and −9.4 kcal/mol for pristimerin, which indicate that all three natural products are good inhibitors. Each of these methide-quinones is closely related to the methide-quinone Br derivative mentioned above [ 35 ]. That these interactions remain after the more rigorous molecular dynamics calculations underscores their significance.…”
Section: Discussionmentioning
confidence: 99%
“…The prospect of clinical intervention of regulated necrosis pathways, such as disulfiram to inhibit GSDM pore formation (63), NLRP3 inflammasome inhibitors (55), and RIPK1 inhibitors (103), has also been investigated for the therapeutic treatment of inflammatory and degenerative diseases by intervening in necroptotic signaling, for use against inflammatory bowel disease, amyotrophic lateral sclerosis, and Alzheimer's disease (35,103,122).…”
Section: Exploiting Cell Death Therapeuticallymentioning
confidence: 99%